论文部分内容阅读
目的 :研究CAF方案及CAP方案对乳腺癌术前化疗的疗效及不良反应 ,并比较两方案在卵巢功能正常组及减退组中疗效的差异。方法 :初始的T2 -4N0 -2 M0 期的乳腺癌患者 ,分为CAF组及CAP组 ,每组中根据患者月经状况又分为卵巢功能正常组(月经正常 )及卵巢功能减退组 (开始出现月经紊乱及已绝经者 )分别观察两方案在两组中的疗效。同时观察两方案的不良反应。结果 :全组有效率为 73 8%,其中CAF组 70 3 %,CAP组 77 0 %,统计学处理无显著性差异 (P >0 0 1) ;卵巢功能正常组的有效率 ,CAP方案为 77 8%,CAF方案为 5 8 1%,统计学处理有显著性差异 (P <0 0 5 ) ,卵巢功能减退组的有效率 ,CAF为 84 2 %、CAP为 76 2 %,统计学处理无显著性差异 (P >0 0 1)。主要不良反应为轻中度白细胞下降、恶心呕吐、脱发、肝功能损害 ,两组比较 ,CAP方案的Ⅲ～Ⅳ恶心呕吐反应较CAF为多 ,(P <0 0 1)。其它不良反应两组相近。结论 :CAF及CAP方案均为乳腺癌术前化疗的有效方案 ;两方案不良反应较轻 ,均可耐受。在中青年患者中卵巢功能正常者 ,CAP方案的疗效优于CAF方案
Objective: To study the curative effect and adverse reactions of CAF regimen and CAP regimen on preoperative chemotherapy of breast cancer and to compare the curative effect between the two regimens in normal ovarian function group and hypogonadal group. Methods: The initial T2 -4N0 -2 M0 breast cancer patients were divided into CAF group and CAP group, each group according to the patient’s menstrual status is divided into normal ovarian function group (normal menstruation) and ovarian dysfunction group (began to appear Menstrual disorders and menopause) were observed in two groups in the efficacy of the two groups. At the same time observe the two programs adverse reactions. Results: The effective rate of the whole group was 73.8%, of which 70.3% in the CAF group and 77.0% in the CAP group were not statistically significant (P> 0.01); the effective rate of the normal ovarian function group and the CAP regimen were 77 8%, and CAF regimen was 58.1%, there was a significant difference between the two groups (P <0.05). The effective rate of ovarian dysfunction group was 84.2% for CAF and 76.2% for CAP. Statistical analysis No significant difference (P> 0 0 1). The main adverse reactions were mild to moderate leukopenia, nausea, vomiting, hair loss and liver damage. Compared with CAF, CAP regimen showed more Ⅲ ~ Ⅳ nausea and vomiting (P <0.01). Other adverse reactions similar to the two groups. Conclusions: Both CAF and CAP regimens are effective regimens for preoperative chemotherapy of breast cancer; both regimens are less toxic and tolerable. In young patients with normal ovarian function, CAP program curative effect is better than the CAF program